A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies

ABSTRACT Background Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combination of temsirolimus and capecitabine in patients...

Full description

Bibliographic Details
Main Authors: Neel D. Trivedi, Samantha Armstrong, Hongkun Wang, Marion Hartley, John Deeken, A. Ruth He, Deepa Subramaniam, Heather Melville, Chris Albanese, John L. Marshall, Jimmy Hwang, Michael J. Pishvaian
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Medicine
Subjects:
5‐fluorouracil
capecitabine
colorectal cancer
mTOR
temsirolimus
Online Access:https://doi.org/10.1002/cam4.3672

Internet

https://doi.org/10.1002/cam4.3672

Similar Items